安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- People With Severe Diabetes Are Cured in Small Trial of New Drug
A person’s conventional supplies for treating type 1 diabetes A single infusion of a new treatment, called zimislecel, may have cured 10 out of 12 people with the most severe form of the disease
- Seeking Multiorgan Benefits with Cardiovascular–Kidney . . .
The evidence is robust, and the indication to use the drug for cardiovascular prevention in persons with type 2 diabetes Notes Disclosure forms provided by the author are available with the
- People with Severe Type 1 Diabetes are Cured in Small Trial . . .
"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times "One year later, these 10 patients no longer need insulin The other two patients need much lower doses " The experimental treatment, cal
- Oral Semaglutide Significantly Improves Cardiovascular . . .
Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s A recent study found that oral semaglutide offers meaningful cardiovascular benefits for people with type 2 diabetes, lowering risk by 14% Results from the Semaglutide Cardiovascular Outcomes Trial (SOUL) were unveiled as a late-breaking symposia at American Diabetes Asso
- Mount Sinai Researchers Move Closer to a Cure for Diabetes
Diabetes researchers and bioinformaticians from the Icahn School of Medicine at Mount Sinai have developed a new understanding of how human beta cell regenerative drugs work These drugs, developed at Mount Sinai, may hold promise for more than 500 million people with diabetes in the world
- New Diabetes Drug Approvals in 2025: What Clinicians Need to Know
Clinician reviewing new diabetes drug guidelines for 2025 In 2025, diabetes care is evolving rapidly, driven by new pharmaceutical innovations that promise more precise, effective, and patient-friendly treatment options For clinicians, staying informed about the latest approved diabetes drugs is crucial for optimizing patient outcomes From
- New Pill Form of Semaglutide Shows Major Benefits for People . . .
A large clinical trial found that oral semaglutide reduces major cardiovascular events by 14% in people with type 2 diabetes and related conditions, offering a promising alternative to the injectable form The results mirror prior findings and suggest broader treatment flexibility
|
|
|